Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets
Seer (Nasdaq: SEER) adopted a limited-duration tax benefit preservation plan to protect approximately $262 million of net operating loss carryforwards as of December 31, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer (Nasdaq: SEER) adopted a limited-duration tax benefit preservation plan to protect approximately $262 million of net operating loss carryforwards as of December 31, 2025. The plan seeks to limit ownership accumulation above 4.9% of Class A stock without Board approval.
The Board declared a dividend of one transferable right per outstanding Class A share, with a record date of March 9, 2026. The NOL Plan expires February 25, 2029, or earlier on February 25, 2027 if shareholders do not ratify it at Seer’s 2026 annual meeting.
Positive
- $262 million of NOLs identified for preservation
- NOL Plan targets ownership shifts to reduce Section 382 impairment risk
- Board-declared rights provide a structured protective mechanism
Negative
- Plan restricts additional acquisitions above 4.9% without Board approval, potentially deterring investors
- If not ratified, the plan expires early on February 25, 2027, shortening protection window
Details
News Market Reaction – SEER
On Feb 27, the first trading day after this news, SEER closed 17.31% below the previous close.
Data tracked by StockTitan Argus for the Feb 27 session.
Key Figures
- Net operating losses
- $262 million
- NOLs as of December 31, 2025
- Ownership threshold
- 4.9%
- Beneficial ownership level that triggers NOL Plan disincentive
- "5% stockholders"
- 5%
- Holders counted for Section 382 ownership change test
- Ownership change test window
- 3 years
- Rolling three-year period for Section 382 ownership-change calculation
- Ownership change trigger
- More than 50 percentage points
- Increase in 5% stockholders’ aggregate ownership over lowest level
- Record date for rights dividend
- March 9, 2026
- Shareholders of record receive one right per Class A share
- Plan expiration if ratified
- February 25, 2029
- Scheduled NOL Plan expiration with shareholder ratification
- Plan expiration if not ratified
- February 25, 2027
- Early termination date if shareholders do not ratify NOL Plan
Historical Context
-
Activist group pressed for governance and operational changes after steep share decline.
-
Researchers highlighted Proteograph’s role and advanced proteomic capabilities at US HUPO 2026.
-
Announcement of management participation and fireside chat at TD Cowen conference.
-
Scheduled date and webcast details for Q4 and full-year 2025 results release.
-
Nature Genetics study validated Proteograph for population-scale proteomics and pQTL work.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
tax benefit preservation plan financial
net operating loss carryforwards financial
nols financial
section 382 regulatory
internal revenue code regulatory
ownership change regulatory
5% stockholders financial
record date financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan (“NOL Plan”) designed to help preserve and protect Seer’s valuable income tax net operating loss carryforwards and other tax assets (“NOLs”).
As of December 31, 2025, Seer had approximately
The NOL Plan is similar to those adopted by numerous other public companies with significant NOLs. The NOL Plan helps to reduce the risk of substantial impairment to the NOLs that could result from an “ownership change” within the meaning of Section 382 of the Internal Revenue Code. In general, an “ownership change” would occur if the Company’s “
Seer intends to submit the NOL Plan to its shareholders for ratification at Seer’s 2026 annual meeting. The NOL Plan is not designed to prevent any action that the Board of Directors determines to be in the best interest of Seer and all of its shareholders.
The NOL Plan aims to preserve the NOLs by creating a disincentive for any shareholder to accumulate beneficial ownership of
In connection with its adoption of the NOL Plan, the Board of Directors declared a dividend of one “right” for each outstanding share of Seer’s Class A common stock. The dividend will be made to shareholders of record as of the close of business on March 9, 2026. Any shares of Seer’s Class A common stock that are issued after the record date will be issued together with a right. The distribution of the rights is not taxable to Seer or its shareholders.
The NOL Plan expires on February 25, 2029. However, if shareholders do not ratify the NOL Plan at Seer’s 2026 annual meeting, the NOL Plan will expire on February 25, 2027.
Additional information about the NOL Plan will be available on a Form 8-K to be filed by Seer with the U.S. Securities and Exchange Commission.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the protection of the NOLs and their value to Seer. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Kelly Gura
investor@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.